Clinical effect of adjuvant chemotherapy with DOS regimen in advanced gastric cancer
Author(s): WANG Rong, WANG Yang, WANG Dan, CHEN Xuan, HAN Cuie, LI Fengjuan
Pages: 673-675,691
Year: 2017 Issue: 6
Journal: Oncology Progress
Keyword: advanced gastric cancer; docetaxel; oxaliplatin; S-1; adjuvant chemotherapy;
Abstract: Objective To explore the clinical efficacy of preoperative adjuvant chemotherapy with the combination of docetaxel, oxaliplation and S-1 (DOS) in patients with advanced gastric cancer. Method 88 cases of advanced gastric cancer patients who had undergone surgery were enrolled and retrospectively analyzed. The patients were divided into chemotherapy group and surgery alone group according to their treatment regimens, with 44 cases in each group. The pa-tients in the chemotherapy group were given preoperative adjuvant chemotherapy with DOS regimen, and those in sur-gery alone group were treated with surgery alone. The surgery conditions, complications and long-term survival rate were compared between two groups. Result In the 44 patients of chemotherapy group, one patient failed to completed the first chemotherapy cycle, and the total effective rate of chemotherapy was 95.35%;the intraoperative blood loss and the number of positive lymph nodes in the chemotherapy group were significantly lower than those in the surgery alone group (P<0.001). The R0 resection rate in the chemotherapy group was higher than that in the surgery alone group (P<0.05);the 2-year recurrence rate after surgery in chemotherapy group was lower than that in surgery alone group, while the 2-year survival rate in chemotherapy group was higher than that in surgery alone group, but there was no statistically significant difference observed (P>0.05). Conclusion Preoperative DOS adjuvant chemotherapy is conducive to improv-ing the efficacy of radical surgery for advanced gastric cancer, and has a beneficial impact on long-term survival.
Pages: 673-675,691
Year: 2017 Issue: 6
Journal: Oncology Progress
Keyword: advanced gastric cancer; docetaxel; oxaliplatin; S-1; adjuvant chemotherapy;
Abstract: Objective To explore the clinical efficacy of preoperative adjuvant chemotherapy with the combination of docetaxel, oxaliplation and S-1 (DOS) in patients with advanced gastric cancer. Method 88 cases of advanced gastric cancer patients who had undergone surgery were enrolled and retrospectively analyzed. The patients were divided into chemotherapy group and surgery alone group according to their treatment regimens, with 44 cases in each group. The pa-tients in the chemotherapy group were given preoperative adjuvant chemotherapy with DOS regimen, and those in sur-gery alone group were treated with surgery alone. The surgery conditions, complications and long-term survival rate were compared between two groups. Result In the 44 patients of chemotherapy group, one patient failed to completed the first chemotherapy cycle, and the total effective rate of chemotherapy was 95.35%;the intraoperative blood loss and the number of positive lymph nodes in the chemotherapy group were significantly lower than those in the surgery alone group (P<0.001). The R0 resection rate in the chemotherapy group was higher than that in the surgery alone group (P<0.05);the 2-year recurrence rate after surgery in chemotherapy group was lower than that in surgery alone group, while the 2-year survival rate in chemotherapy group was higher than that in surgery alone group, but there was no statistically significant difference observed (P>0.05). Conclusion Preoperative DOS adjuvant chemotherapy is conducive to improv-ing the efficacy of radical surgery for advanced gastric cancer, and has a beneficial impact on long-term survival.
Related Articles